A Weekly Insulin Is Now FDA-Approved

The Approval That Changes Basal Insulin

The diabetes community welcomed its second approved once-weekly insulin on September 24, 2026, as the US Food and Drug Administration (FDA) approval of insulin efsitora alfa-gobe (Onswik) for adults with type 2 diabetes less than 7 months after the approval of insulin icodec (Awiqli).

FDA has approved insulin efsitora alfa-gobe (Onswik), Eli Lilly and Company's once-weekly basal insulin, on September 24, 2026, as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes.

Brand, Generic Name and How It Works

The drug is marketed as Onswik (insulin efsitora alfa-gobe), a long-acting insulin injected once a week. The FDA's 2026 novel drug approvals list dates the approval to Sept. 23, and Eli Lilly announced it the next day.

According to Eli Lilly, efsitora is designed to maintain steady basal insulin levels across a full 7-day dosing interval, reducing basal injections from approximately 365 to 52 per year vs once-daily basal insulin. The once-weekly efsitora regimen is designed to reduce injections by over 300 per year versus once-daily basal insulin.

The QWINT Data Behind Approval

The approval is based on the QWINT phase 3 clinical trial program, which enrolled more than 3400 adults with type 2 diabetes across 4 global registration studies. Onswik achieved noninferior A1C reductions compared with daily insulin glargine or insulin degludec.

Hosts on Diabetes Dialogue examined the approval, the phase 3 QWINT data, hypoglycemia edge, and dosing tips, noting that efsitora's steady profile may help patients who struggle with daily adherence.

Not for Type 1, Not Yet for Everyone

Once-weekly insulin Onswik approved for adults with type 2 diabetes but not recommended for Type 1 patients. The FDA label specifies adjunct to diet and exercise for type 2 diabetes only, with safety data in type 1 still under evaluation due to hypoglycemia risk.

While not yet available in pharmacies at approval, Onswik injection for subcutaneous use is instructed to be injected on the same day of the week, similar to GLP-1 agonists patients already know.A Weekly Insulin Is Now FDA-Approved

The Approval That Changes Basal Insulin

The diabetes community welcomed its second approved once-weekly insulin on September 24, 2026, as the US Food and Drug Administration (FDA) approval of insulin efsitora alfa-gobe (Onswik) for adults with type 2 diabetes less than 7 months after the approval of insulin icodec (Awiqli).

FDA has approved insulin efsitora alfa-gobe (Onswik), Eli Lilly and Company's once-weekly basal insulin, on September 24, 2026, as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes.

Brand, Generic Name and How It Works

The drug is marketed as Onswik (insulin efsitora alfa-gobe), a long-acting insulin injected once a week. The FDA's 2026 novel drug approvals list dates the approval to Sept. 23, and Eli Lilly announced it the next day.

According to Eli Lilly, efsitora is designed to maintain steady basal insulin levels across a full 7-day dosing interval, reducing basal injections from approximately 365 to 52 per year vs once-daily basal insulin. The once-weekly efsitora regimen is designed to reduce injections by over 300 per year versus once-daily basal insulin.

The QWINT Data Behind Approval

The approval is based on the QWINT phase 3 clinical trial program, which enrolled more than 3400 adults with type 2 diabetes across 4 global registration studies. Onswik achieved noninferior A1C reductions compared with daily insulin glargine or insulin degludec.

Hosts on Diabetes Dialogue examined the approval, the phase 3 QWINT data, hypoglycemia edge, and dosing tips, noting that efsitora's steady profile may help patients who struggle with daily adherence.

Not for Type 1, Not Yet for Everyone

Once-weekly insulin Onswik approved for adults with type 2 diabetes but not recommended for Type 1 patients. The FDA label specifies adjunct to diet and exercise for type 2 diabetes only, with safety data in type 1 still under evaluation due to hypoglycemia risk.

While not yet available in pharmacies at approval, Onswik injection for subcutaneous use is instructed to be injected on the same day of the week, similar to GLP-1 agonists patients already know.

Second Weekly Insulin in 2026

This is the second weekly basal approval in 2026. The first, insulin icodec (Awiqli) from Novo Nordisk, was approved in February 2026. Having two weekly options creates competition on device, titration and pricing, and validates weekly basal as a class.

The approval represents the fourth global regulatory clearance for the agent, following earlier actions by the European Medicines Agency (EMA), Mexico's COFEPRIS, and Japan's PMDA.

Why Weekly Matters for Adherence

Big Change for Insulin Users with Type 2 Diabetes: reducing the number of injections from 365 to 52 transforms adherence. Studies show daily basal adherence drops after six months; weekly dosing aligns with existing weekly GLP-1 habits and reduces injection burden.

For health systems, fewer injections mean less training, less waste and potentially better persistence, important as diabetes prevalence rises and workforce shortages affect primary care.

Practical Next Steps for Patients

September 2026 brought several FDA actions including finerenone for CKD in type 1, Onswik for type 2, and Beta Bionics' Mint smartphone-controlled insulin patch pump clearance. Patients on daily glargine or degludec should discuss switching only after pharmacy availability, titration plans and hypoglycemia education, as weekly insulins require different dose calculations.

Expect payer coverage decisions in Q4 2026, with Lilly offering bridge programs similar to other launches.

Working Source Links:

Weekly Insulin Efsitora Alfa (Onswik) Gains FDA approval for Type 2 Diabetes - https://www.hcplive.com/view/insulin-efsitora-alfa-onswik-gains-fda-approval-for-type-2-diabetes

FDA Approves Lilly's Insulin Efsitora Alfa-Gobe (Onswik) for Type 2 Diabetes - https://www.biopharminternational.com/view/fda-approves-lilly-insulin-efsitora-alfa-gobe-onswik-type-2-diabetes

FDA approves Eli Lilly's weekly insulin injection - https://www.beckershospitalreview.com/pharmacy/fda-approves-eli-lillys-weekly-insulin-injection/

Once-Weekly Insulin Onswik Approved for Adults with Type 2 Diabetes but Not Recommended for Type 1 - https://www.medicaldaily.com/onswik-weekly-insulin-fda-approval-type-2-diabetes-not-type-1-479170

Diabetes Dialogue: Weekly Insulin Efsitora Alfa Gets FDA Approval - https://www.hcplive.com/view/diabetes-dialogue-weekly-insulin-efsitora-alfa-gets-fda-approval-for-type-2-diabetes